How an inhaled drug could stop Covid’s most severe symptoms
Multiple sclerosis treatment could be repurposed to cut serious respiratory problems
![A nurse wearing PPE cares for a patient in intensive care](https://cdn.mos.cms.futurecdn.net/tkuTofJM3Bg7C4T4bw6i28-415-80.jpg)
A major trial of a drug which could stop Covid-19 patients from developing serious respiratory problems is giving hope that infections could become more treatable in the future.
The treatment involves inhaling a protein called interferon beta, which the body produces when it gets a viral infection, and is being studied in a mass trial overseen by the University of Southampton.
Early findings published in The Lancet last year suggested the treatment, developed at Southampton University Hospital and produced by Southampton-based biotech company Synairgen, cut the odds of a Covid patient developing severe disease by almost 80%.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
![https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg](https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516-320-80.jpg)
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
How does it work?
Interferon beta, which is regularly used in the treatment of multiple sclerosis, is part of the body’s first natural line of defence against viruses, warning it to expect a viral attack.
Experts believe that Covid-19 blocks the production of interferon beta as part of its strategy to evade our immune systems. However, the new treatment sees it delivered directly into the airways via a nebuliser that makes the protein into an aerosol.
It is hoped that a direct dose of the protein in the lungs will trigger a strong anti-viral response. The Lancet study found that patients given interferon beta were not only less likely to develop severe respiratory problems, but that even patients who had already developed serious breathing problems were twice as likely to recover fully over a 16-day treatment period.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
What next?
Writing on The Conversation, Gordon Dent, a senior lecturer in pharmacology at Keele University, says that “these results need to be confirmed in larger studies comparing the drug with other treatments”, adding that the drug’s efficacy is also being “investigated in combination with other therapies, including remdesivir”.
The team running the trial, which includes 600 patients in 20 countries, say they hope it will be completed by early summer.
Tom Wilkinson, professor of respiratory medicine at the University of Southampton, said: “If we had a positive study, we would hope to move rapidly into scaled manufacture and delivery of the drug in clinical practice.”
Create an account with the same email registered to your subscription to unlock access.
Chas Newkey-Burden has been part of The Week Digital team for more than a decade and a journalist for 25 years, starting out on the irreverent football weekly 90 Minutes, before moving to lifestyle magazines Loaded and Attitude. He was a columnist for The Big Issue and landed a world exclusive with David Beckham that became the weekly magazine’s bestselling issue. He now writes regularly for The Guardian, The Telegraph, The Independent, Metro, FourFourTwo and the i new site. He is also the author of a number of non-fiction books.
-
Quiz of The Week: 20 - 26 July
Puzzles and Quizzes Have you been paying attention to The Week's news?
By The Week Staff Published
-
The Week Unwrapped: The dark world of illicit gambling
Podcast Plus, the pension pot shortfall and Obama's silence on Harris
By The Week Staff Published
-
Leonora Carrington: Rebel Visionary – an exhibition of 'unearthly delights'
The 'captivating' show features over 70 pieces spanning everything from paintings to tapestries
By The Week UK Published
-
Brexit, Matt Hancock and black swans: five takeaways from Covid inquiry report
The Explainer UK was 'unprepared' for pandemic and government 'failed' citizens with flawed response, says damning report
By Harriet Marsden, The Week UK Published
-
Should masks be here to stay?
Talking Points New York Governor Kathy Hochul proposed a mask ban. Here's why she wants one — and why it may not make sense.
By Anya Jaremko-Greenwold, The Week US Published
-
Covid might be to blame for an uptick in rare cancers
The explainer The virus may be making us more susceptible to certain cancers
By Devika Rao, The Week US Published
-
Long Covid and chronic pain: is it all in the mind?
The Explainer 'Retraining the brain' could offer a solution for some long Covid sufferers
By The Week UK Published
-
Covid four years on: have we got over the pandemic?
Today's Big Question Brits suffering from both lockdown nostalgia and collective trauma that refuses to go away
By Chas Newkey-Burden, The Week UK Published
-
The hollow classroom
Opinion Remote school let kids down. It will take much more than extra tutoring for kids to recover.
By Mark Gimein Published
-
Excess screen time is making children only see what is in front of them
Under the radar The future is looking blurry. And very nearsighted.
By Devika Rao, The Week US Published
-
Covid-19: what to know about UK's new Juno and Pirola variants
in depth Rapidly spreading new JN.1 strain is 'yet another reminder that the pandemic is far from over'
By Arion McNicoll, The Week UK Published